Research Progress on Interleukin-6 Inhibitors in the Treatment of Rheumatoid Arthritis
10.3870/j.issn.1004-0781.2017.06.012
- VernacularTitle:白细胞介素-6抑制药治疗类风湿关节炎的研究进展
- Author:
Yue CHEN
- Keywords:
Tocilizumab;
Interleukin-6 inhibitors;
Rheumatoid arthritis;
Interleukin-6
- From:
Herald of Medicine
2017;36(6):646-649
- CountryChina
- Language:Chinese
-
Abstract:
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by polyarthritis.Numerous agents with varying mechanisms are used in the treatment of RA,but there is no radical cure.Interleukin-6 (IL-6) plays an important role in the pathogenesis of RA.Agents targeting IL-6 such as tocilizumab (TCZ) attracted significant attention as a promising agent in RA treatment.This article reviewed the key efficacy and safety data from clinical trials of TCZ,as well as six candidate IL-6 blockers including sarilumab,ALX-0061,sirukumab,MEDI5117,clazakizumab,and olokizumab,and their future perspectives in the treatment of RA.
